Di Fan | Molecular Imaging in Drug Development | Best Researcher Award

Ms. Di Fan | Molecular Imaging in Drug Development | Best Researcher Award

Capital Medical University | China

AUTHOR PROFILE

Scopus

πŸ“Œ DI FAN, PhD

Associate Researcher
Department of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University

πŸŽ“ EDUCATION AND EARLY ACADEMIC PURSUITS

Di Fan pursued his Bachelor’s degree at Wuhan University (2006-2010), where he built a strong foundation in biomedical sciences. His passion for advanced medical research led him to Peking University (2010-2015), where he obtained his PhD. During his doctoral studies, he focused on radiopharmaceuticals and molecular imaging, setting the stage for a career dedicated to cutting-edge advancements in nuclear medicine.

πŸ₯ PROFESSIONAL ENDEAVORS

Currently serving as an Associate Researcher at the Department of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Di Fan plays a pivotal role in advancing molecular imaging and targeted cancer therapies. His work bridges the gap between innovative radiopharmaceuticals and their clinical applications, contributing to the early detection and treatment of cancer.

πŸ”¬ CONTRIBUTIONS AND RESEARCH FOCUS

Dr. Fan’s research is primarily focused on:

  • Radiopharmaceutical Development – Designing novel radioactive tracers for precise cancer imaging and treatment.
  • Molecular Imaging – Utilizing advanced PET and SPECT imaging techniques to enhance tumor detection and therapeutic monitoring.
  • Targeted Cancer Therapy – Developing radiolabeled compounds to selectively attack cancer cells, minimizing damage to healthy tissues.

His work contributes significantly to improving personalized cancer treatment, ensuring higher accuracy in diagnosis and therapy.

🌍 IMPACT AND INFLUENCE

Dr. Fan’s contributions have been recognized through numerous scientific publications, collaborations with leading medical institutions, and participation in national and international research projects. His expertise in nuclear medicine and molecular imaging has influenced both clinical practices and medical innovations in China and beyond.

πŸ“š ACADEMIC CITES AND RECOGNITION

  • Published extensively in high-impact SCI-indexed journals related to radiopharmaceuticals and cancer imaging.
  • H-index and citations reflect his significant contribution to the field of nuclear medicine.
  • Regularly invited to present at global medical and radiology conferences, sharing insights on novel imaging techniques.

πŸš€ LEGACY AND FUTURE CONTRIBUTIONS

Dr. Fan aims to:
βœ… Develop next-generation radiopharmaceuticals for better cancer detection and treatment.
βœ… Strengthen collaborations between academic and clinical institutions to enhance nuclear medicine applications.
βœ… Advance precision oncology, integrating AI-driven analysis for personalized cancer therapies.

His research will continue shaping the future of molecular imaging and targeted therapies, ensuring breakthroughs in early cancer diagnosis and patient-centered treatments.

🧬CONCLUSION

Dr. Di Fan stands at the forefront of nuclear medicine research, making significant strides in radiopharmaceuticals, molecular imaging, and targeted cancer therapy. His dedication to scientific innovation and clinical application has not only enhanced cancer diagnostics and treatment but also paved the way for more effective and personalized medical approaches.

 

πŸ“ŠπŸ”¬NOTABLE PUBLICATION:
    1. Title: Utilisation of the Innovative [18F]-Labelled Radiotracer [18F]-BIBD-071 Within HR+ Breast Cancer Xenograft Mouse Models
      Authors: D., Fan, Di , X., Wang, Xin , X., Ling, Xueyuan , … Z., Wu, Zehui , L., Ai, Lin
      Journal: Pharmaceuticals
      Year: 2025

Dr. Lei Xia | Theranostics | Best Researcher Award

Dr. Lei Xia | Theranostics | Best Researcher Award

Peking University Cancer Hospital |Β  China

Author Profile

Scopus

Orcid Id

Dr. Xia Lei, PhD 🧬

Affiliation:
Department of Nuclear Medicine, Peking University Cancer Hospital
Physician, Associate Researcher

Contact Information:
πŸ“ž Phone: 18811177191
βœ‰οΈ Email: xialei9012288@126.com

Biography:

Dr. Xia Lei, PhD, currently serves as a physician and associate researcher in the Department of Nuclear Medicine at Peking University Cancer Hospital. Dr. Lei graduated from the Medical School of Peking University in 2020. His expertise and research interests lie in the innovative field of nuclear medicine, particularly focusing on the development and clinical application of radiopharmaceutical probes for tumor targeting.

His primary research areas include:

  1. Construction of Tumor-Targeted Multimodal Imaging Molecular Probes 🩻
    • Dr. Lei is dedicated to creating advanced imaging probes that can target tumors with high precision, enhancing the accuracy of tumor detection and diagnosis.
  2. Development and Preliminary Application of Novel Integrated Diagnostic and Therapeutic Probes 🧫
    • He is pioneering the integration of diagnostic and therapeutic functions into single probes, aiming to streamline and improve the effectiveness of cancer treatment.
  3. Preparation and Clinical Translation of Tumor-Targeted Radiopharmaceutical Probes πŸ§ͺ
    • Dr. Lei’s work involves preparing radiopharmaceuticals that specifically target tumors and translating these innovations from the lab to clinical settings to benefit patients.

Principal Investigator in Projects:

Dr. Lei has been the principal investigator for several prestigious projects, showcasing his leadership in research and innovation:

  1. National Natural Science Foundation of China, Young Scientists Fund (NO.82202201) 🌟
    • RMB 300,000 (January 2023 – December 2025)
  2. Young Talents Support Plan by the China Association for Science and Technology (NO. YESS20220230) 🌟
    • RMB 600,000 (January 2023 – December 2025)
  3. Beijing Natural Science Foundation, General Program (NO.7242266) 🌟
    • RMB 200,000 (January 2024 – December 2026)
  4. Peking University Cancer Hospital Science Innovation and Translation Fund 🌟
    • RMB 140,000 (January 2024 – December 2024)
  5. Medical School of Peking University, Young Scientists Innovation Fund 🌟
    • RMB 40,000
  6. Internal Fund of Peking University Cancer Hospital 🌟
    • RMB 80,000
  7. Peking University Cancer Hospital Science Innovation Nurturing Fund 🌟
    • RMB 100,000

Dr. Lei’s contributions to the field of nuclear medicine are instrumental in advancing the understanding and treatment of cancer, reflecting his commitment to medical innovation and patient care.

 

πŸ“ŠπŸ”¬Notable Publication: